| Optimal cervical cytology mass screening interval for cervical cancer. | |
| | |
MedLine Citation:
|
PMID: 23053319 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
OBJECTIVE: To identify the optimal interval for repeat cervical cytology testing for screening of cervical cancer and dysplasia in healthy female adults. DESIGN AND METHODS: A retrospective cohort study was conducted on 3,804 apparently healthy females without known cervical cancer at baseline from 2005 to 2010. Participants underwent annual health checkups, including cervical cytology testing. This data did not contain human papillomavirus status. Participants with cytological abnormality underwent further examination, including biopsy, to check for cervical cancer. The generalized estimating equation (GEE) was performed to analyze the longitudinal data. RESULTS: In the groups <40, 40-49, 50-59 and ≥60 years old, the 5-year cumulative incidences (95 % CI) of cytological abnormality were 11.2 % (8.8-13.9 %), 7.6 % (6.2-9.3 %), 4.4 % (3.3-5.7 %) and 2.8 % (1.8-4.2 %), respectively, and the cumulative incidences of cervical cancer were 0.9 % (0.3-2.0 %), 0.1 % (0.0-0.4 %), 0.1 % (0.0-0.5 %) and 0 %, respectively. The odds ratios of the incidence for cervical cancer and cervical dysplasia per year, with GEE models, were 1.5 (95 % CI:1.1-2.0), 1.2 (95 % CI:0.8-1.9), 2.2 (95 % CI:0.5-10.3) and 0 for cervical cancer, and 1.3 (95 % CI:1.2-1.5), 1.3 (95 % CI:1.2-1.5), 1.3 (95 % CI:1.1-1.5) and 1.4 (95 % CI:0.9-2.0) for cervical dysplasia, respectively. CONCLUSIONS: For patients under 40 years old, the screening for cervical cancer every 2 years should be considered, while for patients of 40-59 years old screening every 2 or 3 years should be considered. Females over 60 years old may only need repeat screening every 5 years. |
| | |
Authors:
|
Daiki Kobayashi; Osamu Takahashi; Chikako Hikosaka; Tomoya Okubo; Tsuguya Fukui |
Related Documents
:
|
23373359 - Preoperative staging of rectal cancer: role of 3d endorectal ultrasonography. 23584349 - Quality indicators in the management of bladder cancer. 23041329 - Health benefits and cost-effectiveness of endoscopic and non-endoscopic cytosponge scre... 22956809 - Enrollment criteria controversies for active surveillance and triggers for conversion t... 23169929 - Vegetarian diets and the incidence of cancer in a low-risk population. 23599029 - A method to identify california's sickle-cell disease population and its linkage to the... 13116019 - Present status of serological tests for cancer. 7517409 - Effect of zatosetron on ipecac-induced emesis in dogs and healthy men. 19679619 - Aging and cancer: converging routes to disease prevention. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-10-11 |
Journal Detail:
|
Title: Archives of gynecology and obstetrics Volume: - ISSN: 1432-0711 ISO Abbreviation: Arch. Gynecol. Obstet. Publication Date: 2012 Oct |
Date Detail:
|
Created Date: 2012-10-11 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8710213 Medline TA: Arch Gynecol Obstet Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Division of General Internal Medicine, Department of Medicine, St. Luke's International Hospital, Tokyo, Japan, daikoba@luke.or.jp. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Validity and efficacy of office hysteroscopy before in vitro fertilization treatment.
Next Document: Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cance...